Want to track CARM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?
CARISMA THERAP (CARM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks | 1 year ago
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates
Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.49 per share a year ago.
Zacks | 1 year ago
2025 © Marketlog. All Rights Reserved.
